Jacobs Levy Equity Management
OLMA icon

Jacobs Levy Equity Management’s Olema Pharmaceuticals OLMA Stock Holding History

Jacobs Levy Equity Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-194,450
Closed -$828K – 1070
2025
Q2 		$828K Buy
194,450
+119,531
+160% +$533K ﹤0.01% 791
2025
Q1 		$282K Hold
74,919
– – ﹤0.01% 988
2024
Q4 		$437K Hold
74,919
– – ﹤0.01% 830
2024
Q3 		$895K Sell
74,919
-12,478
-14% -$160K ﹤0.01% 743
2024
Q2 		$946K Buy
87,397
+12,478
+17% +$135K ﹤0.01% 756
2024
Q1 		$848K Sell
74,919
-74,740
-50% -$964K ﹤0.01% 746
2023
Q4 		$2.1M Sell
149,659
-94,813
-39% -$1.27M 0.01% 594
2023
Q3 		$3.02M Buy
244,472
+169,553
+226% +$1.73M 0.02% 481
2023
Q2 		$677K Sell
74,919
-155,649
-68% -$940K ﹤0.01% 764
2023
Q1 		$800K Buy
230,568
+178,740
+345% +$729K ﹤0.01% 742
2022
Q4 		$127K Sell
51,828
-28,091
-35% -$81.9K ﹤0.01% 923
2022
Q3 		$221K Buy
+79,919
New +$339K ﹤0.01% 924

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Jacobs Levy Equity Management's OLMA Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Olema Pharmaceuticals (OLMA) in Q3 2025, closing a stake of 194,450 shares — an estimated $828K sold.

Jacobs Levy Equity Management first reported a position in OLMA in Q3 2022 and held it in 12 quarters. The position peaked at $3.02M in Q3 2023. 126 funds tracked by Wall St. Rank hold OLMA as of Q3 2025.

  • Jacobs Levy Equity Management reported no remaining Olema Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 194,450 Olema Pharmaceuticals shares in Q3 2025, an estimated $828K.
  • Jacobs Levy Equity Management first reported a position in Olema Pharmaceuticals in Q3 2022 and held it in 12 quarters.
  • Jacobs Levy Equity Management's Olema Pharmaceuticals position peaked at $3.02M in Q3 2023.
  • 126 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.